Polycystic liver disease: A clinical review

Annals of Hepatology

Volumn 11, Issue 6, 2012, Pages 819-826

  Chandok, Natasha ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Cysts; Polycystic liver disease; Treatment

Indexed keywords

ALCOHOL; ANGIOPEPTIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MINOCYCLINE; MONOETHANOLAMINE OLEATE; OCTREOTIDE; PLACEBO; RAPAMYCIN; SOMATOSTATIN DERIVATIVE; TACROLIMUS; TETRACYCLINE;

ASPIRATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FENESTRATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LIVER POLYCYSTIC DISEASE; LIVER RESECTION; LIVER TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCLEROTHERAPY; UNSPECIFIED SIDE EFFECT;

EID: 84869471263     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31406-1     Document Type: Review

References (43)

1. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. Hepatology [Review] 2010; 52: 2223-30.
2. Everson GT, Helmke SM, Doctor B. Advances in manage-ment of polycystic liver disease. Expert review of gas-troenterology & hepatology. [Review] 2008; 2: 563-76.
3. Qian Q, Li A, King BF, Kamath PS, Lager DJ, Huston J 3rd, Shob C, et al. Clinical profile of autosomal dominant po-lycystic liver disease. Hepatology 2003; 37: 164-71.
4. Temmerman F, Missiaen L, Bammens B, Laleman W, Cassi-man D, Verslype C, van Pelt J, et al. Systematic review: the pathophysiology and management of polycystic liver disease. Alimentary pharmacology & therapeutics [Re-search Support, Non-U.S. Gov't Review] 2011; 34: 702-13.
5. Qian Q. Isolated polycystic liver disease. Advances in chronic kidney disease. [Research Support, N.I.H., Extra-mural Research Support, Non-U.S. Gov't Review] 2010; 17: 181-9.
6. Drenth JP, Martina JA, Te Morsche RH, Jansen JB, Boni-facino JS. Molecular characterization of hepatocystin, the protein that is defective in autosomal dominant polycystic liver disease. Gastroenterology 2004; 126: 1819-27.
7. Davila S, Furu L, Gharavi AG, Tian X, Onoe T, Qian Q, Li A, et al. Mutations in SEC63 cause autosomal dominant po-lycystic liver disease. Nat Genet 2004; 36: 575-7.
8. Li A, Davila S, Furu L, Qian Q, Tian X, Kamath PS, King BF, et al. Mutations in PRKCSH cause isolated autosomal domi-nant polycystic liver disease. Am J Hum Genet 2003; 72: 691-703.
9. Gao H, Wang Y, Wegierski T, Skouloudaki K, Putz M, Fu X, Engel C, et al. PRKCSH/80K-H, the protein mutated in po-lycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation. Hum Mol Genet 2010; 19: 16-24.
10. Waanders E, Venselaar H, Te Morsche RH, de Koning DB, Kamath PS, Torres VE, Somlo S, et al. Secondary and ter-tiary structure modeling reveals effects of novel mutatio-ns in polycystic liver disease genes PRKCSH and SEC63. Clin Genet 2010; 78: 47-56.
11. Torres VE, Harris PC. Autosomal dominant polycystic kid-ney disease: the last 3 years. Kidney Int 2009; 76: 149-68.
12. Pirson Y. Extrarenal manifestations of autosomal domi-nant polycystic kidney disease. Advances in chronic kid-ney disease. [Review] 2010; 17: 173-80.
13. Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson ML, Duley IT, Everson GT. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 1990; 11: 1033-7.
14. Grunfeld JP, Albouze G, Jungers P, Landais P, Dana A, Droz D, Moynot A, et al. Liver changes and complications in adult polycystic kidney disease. Adv Nephrol Necker Hosp 1985; 14: 1-20.
15. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, et al. Magnetic reso-nance imaging evaluation of hepatic cysts in early autoso-mal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006; 1: 64-9.
16. Bergmann C, Senderek J, Kupper F, Schneider F, Dornia C, Windelen E, Eggermann T, et al. PKHD1 mutations in auto-somal recessive polycystic kidney disease (ARPKD). Human mutation. [Research Support, Non-U.S. Gov't Research Su-pport, U.S. Gov't, P.H.S. Review] 2004; 23: 453-63.
17. Zerres K, Hansmann M, Mallmann R, Gembruch U. Autoso-mal recessive polycystic kidney disease. Problems of pre-natal diagnosis. Prenatal diagnosis. [Case Reports] 1988; 8: 215-29.
18. Masyuk T, Masyuk A, LaRusso N. Cholangiociliopathies: gene-tics, molecular mechanisms and potential therapies. Current opinion in gastroenterology. [Review] 2009; 25: 265-71.
19. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent mo-del of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 2007; 132: 1104-16.
20. Qian Q, Du H, King BF, Kumar S, Dean PG, Cosio FG, Torres VE. Sirolimus reduces polycystic liver volume in ADPKD pa-tients. J Am Soc Nephrol 2008; 19: 631-8.
21. Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, et al. Mammalian target of rapamycin re-gulates vascular endothelial growth factor-dependent li-ver cyst growth in polycystin-2-defective mice. Hepatology. [Research Support, N.I.H., Extramural Re-search Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.] 2010; 51: 1778-88.
22. Hoevenaren IA, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JP, Everson GT. Polycystic liver: clinical cha-racteristics of patients with isolated polycystic liver di-sease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int 2008; 28: 264-70.
23. Gallegos M, Bradly DP, Jakate SM. Image of the month. Po-lycystic liver disease leading to liver failure and transplan-tation. Clin Gastroenterol Hepatol [Case Reports] 2010; 8: A24.
24. Kirchner GI, Rifai K, Cantz T, Nashan B, Terkamp C, Becker T, Strassburg C, et al. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl 2006; 12: 1268-77.
25. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, et al. Randomized clinical trial of long-acting so-matostatin for autosomal dominant polycystic kidney and liver disease. JASN [Randomized Controlled Trial] 2010; 21: 1052-61.
26. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, et al. Lanreoti-de reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2009; 137: 1661-8, e1-2.
27. Arnold HL, Harrison SA. New advances in evaluation and management of patients with polycystic liver disease. Am J Gastroenterol 2005; 100: 2569-82.
28. Gevers TJ, Drenth JP. Somatostatin analogues for treat-ment of polycystic liver disease. Curr Opin Gastroenterol [Review] 2011; 27: 294-300.
29. Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Re-muzzi G, Ruggenenti P. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. CJASN [Randomized Controlled Trial] 2010; 5: 783-9.
30. Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, van Oijen MG, Coudyzer W, Hoffmann AL, et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Alimentary pharmacology & therapeutics. [Research Support, Non-U.S. Gov't] 2012; 35: 266-74.
31. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kid-ney disease. JASN [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.] 2005; 16: 46-51.
32. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, et al. Sirolimus and kidney growth in autoso-mal dominant polycystic kidney disease. N Engl J Med [Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2010; 363:820-9.
33. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, Kunzendorf U, et al. Everolimus in pa-tients with autosomal dominant polycystic kidney di-sease. N Engl J Med [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2010; 363: 830-40.
34. Nakaoka R, Das K, Kudo M, Chung H, Innoue T. Percuta-neous aspiration and ethanolamine oleate sclerothera-py for sustained resolution of symptomatic polycystic liver disease: an initial experience. AJR 2009; 193: 1540-5.
35. Kairaluoma MI, Leinonen A, Stahlberg M, Paivansalo M, Ki-viniemi H, Siniluoto T. Percutaneous aspiration and alco-hol sclerotherapy for symptomatic hepatic cysts. An alternative to surgical intervention. Ann Surg 1989; 210: 208-15.
36. Nagorney DM, Schnelldorfer T, Torres VE, Rosen CB. Re-section and Fenestration for Symptomatic Polycystic Li-ver Disease. Ann Surg 2011.
37. van Keimpema L, Drenth JP. Polycystic liver disease: a cri-tical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg [Comment Letter] 2011; 253: 419; author reply 20.
38. Aussilhou B, Doufle G, Hubert C, Francoz C, Paugam C, Pa-radis V, Farges O, et al. Extended liver resection for po-lycystic liver disease can challenge liver transplantation. Ann Surg 2010; 252: 735-43.
39. Arrazola L, Moonka D, Gish RG, Everson GT. Model for end-stage liver disease (MELD) exception for polycys-tic liver disease. Liver Transpl 2006; 12(12 Suppl. 3): S110-S111.
40. van Keimpema L, Nevens F, Adam R, Porte RJ, Fikatas P, Becker T, Kirkegard P, et al. Excellent survival after liver transplantation for isolated polycystic liver disease: An European Liver Transplant Registry study. Transplant In-ternational: Official Journal of the European Society for Organ Transplantation [Multicenter Study Research Su-pport, Non-U.S. Gov't] 2011; 24: 1239-45.
41. Simpson N, Cho YW, Cicciarelli JC, Selby RR, Fong TL. Com-parison of renal allograft outcomes in combined liver-kid-ney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database. Transplantation [Research Support, Non-U.S. Gov't] 2006; 82: 1298-303.
42. Chandok N, Uhanova J, Marotta P. Clinical outcomes of li-ver transplantation for polycystic liver disease: a single center experience. Ann Hepatol 2010; 9: 278-81.
43. Pirenne J, Aerts R, Yoong K, Gunson B, Koshiba T, Four-neau I, Mayer D, et al. Liver transplantation for polycys-tic liver disease. Liver Transpl 2001; 7: 238-45.